Bessemer Group Inc. Sells 14,606 Shares of Bruker Corporation $BRKR

Bessemer Group Inc. reduced its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 68.4% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,740 shares of the medical research company’s stock after selling 14,606 shares during the quarter. Bessemer Group Inc.’s holdings in Bruker were worth $244,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Orbis Allan Gray Ltd purchased a new position in Bruker in the 2nd quarter worth approximately $192,735,000. Price T Rowe Associates Inc. MD boosted its position in shares of Bruker by 2,963.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock valued at $111,488,000 after acquiring an additional 2,289,269 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Bruker by 125.3% during the 2nd quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock valued at $137,065,000 after purchasing an additional 1,850,215 shares during the last quarter. Franklin Resources Inc. grew its stake in shares of Bruker by 317.7% during the fourth quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock valued at $108,796,000 after buying an additional 1,756,460 shares during the last quarter. Finally, Millennium Management LLC increased its position in shares of Bruker by 222.6% during the fourth quarter. Millennium Management LLC now owns 1,839,587 shares of the medical research company’s stock worth $86,663,000 after acquiring an additional 1,269,316 shares during the period. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on BRKR. Stifel Nicolaus set a $45.00 price target on Bruker in a report on Friday, May 8th. Leerink Partners boosted their target price on shares of Bruker from $60.00 to $70.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Guggenheim raised their price objective on Bruker from $50.00 to $70.00 and gave the company a “buy” rating in a report on Monday, June 29th. Weiss Ratings upgraded Bruker from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, June 3rd. Finally, TD Cowen reissued a “hold” rating on shares of Bruker in a report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $56.79.

Bruker Stock Performance

Shares of BRKR stock opened at $60.45 on Monday. Bruker Corporation has a 52 week low of $28.53 and a 52 week high of $64.54. The stock has a market capitalization of $9.20 billion, a PE ratio of -251.88, a P/E/G ratio of 1.94 and a beta of 1.29. The company has a quick ratio of 0.72, a current ratio of 1.55 and a debt-to-equity ratio of 0.67. The firm has a 50 day moving average of $56.32 and a two-hundred day moving average of $46.29.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.08. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The business had revenue of $823.40 million during the quarter, compared to analysts’ expectations of $795.62 million. During the same quarter last year, the business posted $0.47 EPS. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, research analysts predict that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd were issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend was Monday, June 22nd. Bruker’s payout ratio is presently -83.33%.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.